Physician

Alba Maria Gonzalez-Ochoa, MD

According to 2025 Medicare claims, Alba Gonzalez-Ochoa, MD (NPI: 1376752816) practices nephrology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is KIDNEY SPECIALTY CENTER INC. (NPI: 1679832679; TIN: 20-8811277) and primary practice location at 33140-2800. Gonzalez-Ochoa is affiliated with the PBACO Holding, LLC (ACO ID: A1001), participating under the MSSP model.

Gonzalez-Ochoa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 332 traditional Medicare patients, billed 2,137 HCPCS/CPT codes, and received $190,625 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,377 prescription claims across 267 beneficiaries totaling $362,831 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2023 DME data shows 48 claims. Open Payments data shows 94 records totaling $16,505. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $113,857 to $190,625. Similarly, Part D prescription costs have risen steadily, from $55,967 to $362,831. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,858 to $970.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	396	1,809	$113,857
2016	378	1,759	$115,742
2017	260	1,214	$79,452
2018	289	1,766	$120,210
2019	287	1,770	$137,367
2020	273	2,072	$187,645
2021	252	1,439	$142,242
2022	339	1,940	$169,879
2023	371	2,171	$188,841
2024	332	2,137	$190,625

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	601	$55,967
2016	87	591	$92,038
2017	85	515	$54,468
2018	84	627	$83,867
2019	93	777	$173,558
2020	116	913	$158,455
2021	155	1,171	$282,350
2022	263	1,405	$374,806
2023	342	2,393	$744,526
2024	267	1,377	$362,831

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$131
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	14	$156
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	48	$1,259
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	55	55	$174
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	79	103	$145
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	198	517	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	84	114	$75
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	111	840	$66

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	158	6,040	$113,476
Jardiance	Empagliflozin	70	2,986	$58,887
Kerendia	Finerenone	44	1,560	$33,888
Procrit	Epoetin Alfa	23	625	$23,383
Ozempic	Semaglutide	17	644	$17,600

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$16,505	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alba Maria Gonzalez-Ochoa, MD?

Tedicare shows public-source Medicare data for Alba Maria Gonzalez-Ochoa, MD (NPI 1376752816), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alba Maria Gonzalez-Ochoa, MD have ACO affiliation data?

Alba Maria Gonzalez-Ochoa, MD is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001).

What billing organization is linked to Alba Maria Gonzalez-Ochoa, MD?

Alba Maria Gonzalez-Ochoa, MD is linked to KIDNEY SPECIALTY CENTER INC. (billing NPI 1679832679) in the available physician profile data.

Does Alba Maria Gonzalez-Ochoa, MD have Open Payments data?

Alba Maria Gonzalez-Ochoa, MD has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.